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Abstract 
Background: The frequency of deficient variants of glucose‑6‑phosphate dehydrogenase (G6PDd) is particularly 
high in areas where malaria is endemic. The administration of antirelapse drugs, such as primaquine, has the potential 
to trigger an oxidative event in G6PD‑deficient individuals. According to Honduras´ national scheme, malaria treat‑
ment requires the administration of chloroquine and primaquine for both Plasmodium vivax and Plasmodium falcipa-
rum infections. The present study aimed at investigating for the first time in Honduras the frequency of the two most 
common G6PDd variants.
Methods: This was a descriptive study utilizing 398 archival DNA samples of patients that had been diagnosed with 
malaria due to P. vivax, P. falciparum, or both. The most common allelic variants of G6PD: G6PD A+376G and G6PD 
A−376G/202A were assessed by two molecular methods (PCR–RFLP and a commercial kit).
Results: The overall frequency of G6PD deficient genotypes was 16.08%. The frequency of the “African” genotype 
A− (Class III) was 11.9% (4.1% A− hemizygous males; 1.5% homozygous A− females; and 6.3% heterozygous A− 
females). A high frequency of G6PDd alleles was observed in samples from malaria patients residing in endemic 
regions of Northern Honduras. One case of Santamaria mutation (376G/542T) was detected.
Conclusions: Compared to other studies in the Americas, as well as to data from predictive models, the present 
study identified a higher‑than expected frequency of genotype A− in Honduras. Considering that the national 
standard of malaria treatment in the country includes primaquine, further research is necessary to ascertain the risk 
of PQ‑triggered haemolytic reactions in sectors of the population more likely to carry G6PD mutations. Additionally, 
consideration should be given to utilizing point of care technologies to detect this genetic disorder prior administra‑
tion of 8‑aminoquinoline drugs, either primaquine or any new drug available in the near future.
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Background
Honduras is a malaria-endemic country where the two 
circulating parasite species are Plasmodium vivax and 
Plasmodium falciparum, with P. vivax being responsi-
ble for 79% of symptomatic cases, which represent more 
than 4,000 cases a year [1]. Honduras has a population 
of approximately 8.7 million, of which 93% is considered 
mestizo (persons of mixed Amerindian and European 
ancestry). Indigenous peoples comprise seven minority 
ethnic groups, making up for less than half a million peo-
ple. The existing ethnic groups of African descent repre-
sent about 5% of the population [2] and are concentrated 
on the Atlantic coast of Northern Honduras, where the 
incidence of malarial infections is higher.
Treatment of P. vivax malaria includes the 8-amino-
quinoline primaquine (PQ), to prevent relapses due to 
dormant liver stages [3]. National guidelines in Hon-
duras follow the World Health Organization (WHO) 
recommendation of 0.25  mg/kg over 14  days for use as 
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a radical cure; i.e., to prevent P. vivax relapse [4]. How-
ever, in some countries this treatment is contraindicated 
in patients with severe deficiency of glucose-6-phosphate 
dehydrogenase (G6PD), as PQ could trigger acute hae-
molysis and/or removal of red blood cells (RBC) by the 
spleen [5, 6].
The geographical distribution of this genetic disor-
der extends through Africa, Asia, Southeast Asia and 
Latin America and overlaps with that of malaria [7]. 
Recent research suggests that as malaria elimination 
efforts intensify, identifying G6PD-deficient (G6PDd) 
individuals prior to treatment is essential to pro-
tect patients from potential haemolytic reactions [8]. 
G6PD is an essential enzyme present in all cells and is 
involved in producing the necessary NADPH required 
for protecting cells against oxidative stress. While 
G6PD deficiency can be compensated by alternate 
pathways in other cells, NADPH is the only mecha-
nism to counter balance oxidative stress in the eryth-
rocyte [9, 10].
The G6PD locus is sex-linked, and the deficiency of 
this enzyme is one of the most prevalent polymorphisms 
causing hereditary enzymopathies in humans, particu-
larly among males who are hemizygous for this trait 
[10–12]. Numerous mutations (186 or more) have been 
identified in the G6DP gene [8, 13], resulting in >400 bio-
chemical variants [14–16].
Due to the large number of variants and differences in 
enzymatic activity, creating a classification system with 
corresponding public health and clinical significance 
has been challenging. A recent proposal, as reviewed 
by Howes et  al. [17] suggests a simplified classification 
including only three types of variants, as follows. Type 1: 
rare, with <10% of enzyme activity, clinically severe and 
chronic; Type 2: more common, with residual enzyme 
activity <1–50%, clinically asymptomatic until triggered 
by an external event; and Type 3: those with more than 
50% of enzyme activity and, therefore, without clini-
cal significance [17, 18]. This classification is not widely 
used. Instead, the WHO recommends utilizing Yoshida’s 
taxonomy, consisting of five classes depending on enzy-
matic activity and clinical manifestations [19, 20]. The 
most severe deficiency is categorized as Class I, with 
variants that albeit rare, are associated with chronic 
haemolytic anaemia. Higher-frequency variants belong 
to classes II and III, and are associated with some degree 
of protection against malaria. Class IV and V are consid-
ered or normal or with increased activity, respectively 
[19]. Among the more prevalent variants, the so-called 
“African” genotype A−202A with 12% of enzymatic activ-
ity is classified as class III, and individuals with such 
variant experience clinical manifestations after specific 
triggers [17]. In turn, genotype A+ gives rise to very-mild 
deficient or normal variants and is included in class IV 
[21–23].
It is widely recognized that deficient variants of G6PD 
are more common in African, Mediterranean, and Asian 
populations [24]. However, research evidence is scant 
from some areas of the world. Recently, Howes et al. set 
out to characterize the spatial distribution of G6PD defi-
ciency variants in areas where malaria is endemic, and 
their findings underscore the scarcity of data from the 
Americas [17]. Similar findings are reported by Monteiro 
et al. [25]. In the Central American region, only Panama 
[26] and Costa Rica [27–30] register publications report-
ing the prevalence of G6PDd. Paradoxically, similar data 
from Honduras, the country with the highest burden of 
malaria in the region [1, 31], is non-existent—no local 
publications or reports in the grey literature could be 
found for the present analysis. No information on the rel-
evance of primaquine-associated haemolysis in Hondu-
ras is available either.
The present study aimed at investigating the frequency 
of the most common G6PDd variants in a subset of Hon-
duran malaria patients. This preliminary information will 
be useful to determine the need for larger population-
based prevalence studies to assess the potential risk of 
haemolytic anaemia due to PQ administration in popula-
tions living in malaria-endemic areas.
Methods
Study area, population and design
This descriptive study included a total of 400 blood 
samples from the same number of Honduran malaria 
patients and collected onto Whatman FTA® cards (GE 
Healthcare). Patients had been routinely assessed for 
malaria by the Honduran Ministry of Health labora-
tory network both by standard microscopy and subse-
quent confirmation by molecular analysis. Cards had 
been stored in the molecular biology laboratory at the 
National Autonomous University of Honduras (UNAH), 
and archived by malaria species diagnosis and patient’s 
provenance, but devoid of patients’ personal information. 
Other than malaria infection, no other clinical informa-
tion (e.g. health status, haemolytic anaemia, etc.) was 
associated with the samples. According to the place of 
origin, samples were from 22 municipalities located in 
five malaria-endemic departments (second-level politi-
cal jurisdictions) of Honduras: Atlántida (n = 35), Colón 
(n  =  45), Gracias a Dios (n  =  133), Islas de la Bahía 
(n = 107), and Olancho (n = 78) (Fig. 1).
Ethical clearance
The study made secondary use of biological specimens 
originally collected for malaria diagnosis as per stand-
ard of care in Honduras. However, as mentioned earlier, 
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blood samples had been anonymized. That is, blood sam-
ples had been irrevocably stripped of direct identifiers, so 
future re-identification of individuals and linkage to the 
G6PD findings was not possible. Scientific approval and 
ethical clearance was obtained from the Ethics Review 
Committee of the Infectious and Zoonotic Diseases Mas-
ters Program at UNAH (CEI-MEIZ 02-2014; 5/19/2014).
Malaria microscopic and molecular diagnosis
As mentioned earlier, samples belonged to malaria-pos-
itive patients previously determined by both microscopy 
and molecular biology. Briefly, experienced microscopists 
at the Ministry of Health laboratories throughout the 
country carried out malaria diagnosis after Giemsa-stain-
ing of thick and thin blood smears. Diagnosis confirma-
tion was done at UNAH as follows. Genomic DNA was 
extracted from Plasmodium-positive filter paper blood 
spots using a Chelex-based method [32]. The detection 
of Plasmodium sp. DNA was performed using an 18S 
rRNA nested PCR approach, according to Singh et  al. 
[33]. Based on both diagnostic methods (microscopy 
and molecular), 322 (80.90%) samples were positive for P. 
vivax, 66 (16.58%) for P. falciparum, and 10 (2.51%) for 
both species (mixed infections) (Table 1).
Since samples were stripped from personal identifiers, 
it was necessary to determine patients’ sex through a 
molecular approach. Two regions of the human sex chro-
mosomes were amplified simultaneously, as described by 
Settin et  al. [34]. Briefly, two sets of primers were used 
in a multiplex PCR. SRYF: 5´-CAT GAA CGC ATT CAT 
CGT GTG GTC-3´ and SRYR: 5´-CTG CGG GAA GCA 
AAC TGC AAT TCT T-3´ for the Y chromosome, and 
ALTF: 5´-CCC TGA TGA AGA ACT TGT ATC TC-3´/
ALTR: 5´-GAA ATT ACA CAC ATA GGT GGC ACT-3´ 
for the X chromosome, with amplicon sizes of 254, and 
300 bp, respectively.
PCR reactions were performed in a 50-μL reaction vol-
ume containing Taq polymerase master mix (Promega 
Corp.), 4  pmol of each primer, and 40  ng of DNA. PCR 
conditions were as follow: 2 min at 94°C and 35 cycles of 
94°C for 30 s, 66°C for 30 s and 72°C for 30 s, and a final 
extension of 15 min at 72°C. PCR products were visual-
ized on 2% agarose gels.
PCR–RFLP for G6PD
Two DNA fragments of the G6PD gene, corresponding 
to exons IV (codon 68, cDNA nucleotide substitution 
202) and V (codon 126, cDNA nucleotide substitution 
376) were PCR amplified independently according to 
protocols previously described [22, 35], with some modi-
fications. Briefly, 20 ng of DNA were added to a final vol-
ume of 50 μL in a reaction mixture containing 2X Taq 
Fig. 1 Map of Honduras and number of samples collected in five departments showing the parasite species causing the malaria infection.
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polymerase Master Mix (Promega Corp.) and 0.4  μM 
of each primer. Primer sequences are shown in Table 2. 
Reaction conditions were as follow: For the region includ-
ing the codon 202: 94°C/10 min, 39 cycles of 94°C/2 min, 
66°C/1  min, and 72°C/2  min. For the region including 
the codon 376: 94°C/10  min, 35 cycles of 94°C/2  min, 
68°C/1  min, and 72°C/2  min. A final extension step of 
10  min was included for all reactions. PCR products of 
898 and 585  bp, respectively were detected in agarose 
gels.
G6PD genotyping was carried out by RFLP of the PCR 
products in order to detect two of the most common 
African variants, G6PD A+ and G6PD A− [36]. The 376 
A →  G mutation leading to the G6PD A+ variant was 
detected through digestion with FokI. All samples show-
ing a G6PD A+ pattern were further analyzed for the 202 
G  →  A mutation, characteristic of the G6PD A− vari-
ant. This genotype was detected by digestion with NlaIII 
as previously described [22]. All digestions were per-
formed at 37°C according to the manufacturer’s instruc-
tions (New England Biolabs) in a final reaction volume 
of 20 μL. FokI digestion was incubated for 60  min and 
NlaIII for 50 min. A 2.5% agarose gel was required to sep-
arate properly the restriction fragments.
The expected pattern of digestion for all genotypes 
(Table  3) was confirmed in silico using the Geneious 
7.1.7 software [37] with wild type and mutant sequences 
obtained from the OMIM database [38].
Confirmation of G6PD variants (Multiplex PCR 
and sequencing)
In addition to the PCR–RFLP analysis, all samples show-
ing a G6PD deficient genotype were screened using Dia-
PlexC™ G6PD Genotyping Kit, African type (SolGent, 
Co., Ltd.), which enables to detect 6 different G6PD vari-
ants by a one-step multi-allelic specific PCR. The six vari-
ants amplify PCR products of different sizes, as follows: 
G6PD A− (202) (376A → G, 103 bp; 202G → A, 157 bp); 
G6PD A+ (376A  →  G, 103  bp); G6PD Santamaria 
(376A → G, 103 bp; 542A → T 241 pb); G6PD A− (680) 
(376A  →  G, 103  bp; 680G  →  T, 388  bp), G6PD A− 
(968) Betica, Selma, Guantanamo (376A  →  G, 103  bp; 
968T → C, 463 bp), G6PD Mediterranean, Dallas, Pan-
ama, “Sassari” (563C →  T, 220  bp). Each PCR reaction 
was confirmed by an internal control (947pb).
For further confirmation of results, a set of 8 ran-
dom samples with G6PD A+ (n  =  4) and G6PD A− 
(n  =  4) genotypes was sequenced. The PCR products 
Table 1 Number of samples collected by sex and parasite species causing the infection
Department n Sex Total P. vivax P. falciparum Mixed infection
n (%) n (%) n (%) n (%)
Atlántida 35 M 16 (4.02) 15 (3.77) 0 1 (0.25)
F 19 (4.77) 18 (4.52) 0 1 (0.25)
Colón 45 M 19 (4.77) 19 (4.77) 0 0
F 26 (6.53) 26 (6.53) 0 0
Gracias a Dios 133 M 59 (14.82) 29 (7.29) 28 (7.04) 2 (0.50)
F 74 (18.59) 35 (8.79) 35 (8.79) 4 (1.01)
Islas de la Bahía 107 M 45 (11.31) 42 (10.55) 1 (0.25) 2 (0.50)
F 62 (15.58) 62 (15.58) 0 0
Olancho 78 M 45 (11.31) 44 (11.06) 1 (0.25) 0
F 33 (8.29) 32 (8.04) 1 (0.25) 0
Total 398 M 184 (46.23) 149 (37.44) 30 (7.54) 5 (1.26)
F 214 (53.77) 173 (43.47) 36 (9.05) 5 (1.26)
398 (100) 322 (80.90) 66 (16.58) 10 (0.02)
Table 2 Primer sequences, exons targeted, and  restriction enzymes used in  the PCR-RFLP assay to  detect two G6PD 
mutations
Variant Sequence (5´–3´) Exon Restriction 
enzyme
References
A− (202 G>A, 376 A>G) GTGGCTGTTCCGGGATGGCCTTCTG AGGGCAACGGCAAGCCTTAC IV, V NlaIII [22, 35]
A+ (376 A>G) CTGCGTTTTCTCCGCCAATC AGGGCAACGGCAAGCCTTAC V FokI [22, 35]
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were purified and sequenced at the Macrogen facili-
ties (macrogenusa.com) using both forward and reverse 
primers. Chromas Pro and Mega5 software were used for 
sequence analysis. Positions 202 and 376 of exons IV and 
V were evaluated searching for the confirmatory SNP.
Data analysis
Data were entered and verified using Microsoft Excel 
software® and exported to SPSS version 21.0 (IBM, 
Armonk, New York, USA) for statistical analysis. Fre-
quency distributions and percentages were calculated 
for sex, malaria infecting species and G6PD variants. 
The measure of agreement between PCR–RFLP and 
DiaPlexCTM G6PD Genotyping Kit (SolGent, Co., Ltd.) 
analysis was assessed by the Cohen’s kappa coefficient. 
A p value <0.05 was considered statistically significant. 
Strengthening the reporting of observational studies in 
epidemiology (STROBE) guidelines were followed when-
ever appropriate in reporting this study (see Additional 
file 1, STROBE statement) [39].
Results
Of the initial 400 samples, 398 were successfully analyzed 
by PCR–RFLP, while the remaining two were excluded 
due to DNA amplification problems. Through genetic 
analysis it was determined that of the 398 samples, 214 
(53.77%) and 184 (46.23%) were from female and male 
individuals, respectively. The frequency of two G6PDd 
allelic variants (A+ and A−) was determined in all sam-
ples. Overall 16% (64/398) of the samples analyzed had a 
G6PD A genotype. The distribution of the frequencies of 
G6PD A genotypes among the participants are shown in 
Tables 4 and 5.
All 398 samples were genotyped by PCR–RFLP for the 
G6PDd A− allele (with two mutations in positions 376 
A → G and 202 G → A). Sixteen (4.02%) were A− males, 
and 31 (7.79%) were A− females. For the G6PDd A+ 
allele (376A  →  G mutation), 4 (1.01%) were A+ males 
and 13 (3.27%) were A+ females (Table 5). The remain-
ing 170 (42.71%) females and 164 (41.21%) males did not 
carry the aforementioned G6PDd alleles.
Of the 398 individuals genotyped by PCR–RFLP, 
17 (4.27%) showed the G6PDd A+ allele, of which 4 
(23.53%) were A+ hemizygous males, 1 (5.88%) was an 
A+ homozygous female, and 12 (70.8%) were A+ hete-
rozygous females. In addition, 47 of 398 (11.81%) samples 
exhibited the G6PD A− allele, of which 16 (34.04%) were 
A− hemizygous males, 6 (12.76%) were A− homozygous 
females, and 25 (53.1%) were A− heterozygous females. 
The remaining 334 (83.92%) individuals, −170 (42.71%) 
females and 164 (41.21%) males—did not carry either 
mutation (Fig. 2; Table 6).
According to these figures, a male: female ratio of 
mutation prevalence was calculated at 1:1.8 (i.e., hemizy-
gous males/(all homozygous females) +  (10% of all het-
erozygous females)  =  16/6  +  (25  ×  0.1%)  =  1:1.88), 
based on previous studies describing this calculation and 
reviewed by Howes et al. [7].
As shown in Table  6, a higher proportion of indi-
viduals with the G6PDd A− genotype were from the 
Table 3 Restriction patterns of normal and mutant individuals by PCR–RFLP
G6PD variant Fragment size (bp)
Restriction patterns
PCR product Wild type Mutant References
A− (202 G>A, 376 A>G) 898 423, 184, 169, 106, 32 423, 184, 127, 106, 46 [22, 35]
A+ (376 A>G) 585 402, 187 289, 187, 117 [22, 35]
Table 4 G6PD genotypes according to sex and Plasmodium species
Genotype n Sex Total P. vivax P. falciparum Mixed infection
n (%) n (%) n (%) n (%)
G6PD B (wildtype) 334 M 164 (41.21) 139 (34.92) 21 (5.28) 4 (1.01)
F 170 (42.71) 145 (36.43) 22 (5.53) 3 (0.75)
G6PD A+ 17 M 4 (1.01) 2 (0.50) 2 (0.50) 0
F 13 (3.27) 10 (2.51) 3 (0.75) 0
G6PD A 47 M 16 (4.02) 8 (2.01) 7 (1.76) 1 (0.25)
F 31 (7.79) 18 (4.52) 11 (2.76) 2 (0.50)
398 (100) 322 (80.90 66 (16.58) 10 (0.02)
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departments of Gracias a Dios (31/133) and Islas de la 
Bahía (10/107).
To confirm the results obtained by PCR–RFLP, all 
64 samples showing a G6PD A+ or G6PD A− geno-
type were analyzed using the commercial kit DiaPlexC™ 
G6PD Genotyping Kit (African type). The kit enables 
the detection of six variants of the G6PD gene, including 
those revealed through PCR–RFLP. Concordant results 
were obtained in all 47 samples with an A− genotype and 
15 of the 17 samples with A+ genotype by PCR–RFLP. 
The discordant results revealed that one sample had an 
A− genotype whereas the other was a Santamaria muta-
tion (376 A → G/542 A → T) (Table 7). In light of the 
absence of prior reports, this is likely the first time the 
Santamaria mutation has been identified in Honduras. 
According to these results, the measure of agreement 
between PCR–RFLP and the commercial Kit revealed a 
Cohen’s kappa coefficient  =  0.923 (Std. error  =  0.052). 
However, since the RFLP assay was not able to detect 
the 542 A →  T mutation, the agreement between both 
approaches increased (k = 0.959).
Of the eight samples with G6PD A+ (n  =  4) and 
A− (n  =  4) restriction patterns selected randomly for 
sequence analysis, all eight had the expected mutation 
in position 376. Conversely, the A− genotype could not 
be demonstrated in any of the four G6PD A− samples 
because of insufficient quality in the obtained sequences. 
A figure summarizing the overall study findings can be 
found as an additional file (see Additional file  2, Flow-
chart with overall study findings).
Discussion
This study presents for the first time, data on the fre-
quency of G6PDd genotypes in Honduras. For the ana-
lyzed samples, the results showed a frequency of G6PD 
A deficient genotypes of 16.08%, and a frequency of 
11.81% with the A− genotype. As this study only aimed 
to detecting two of the most common G6PDd variants 
reported for the Latin American subcontinent, the exist-
ence of less frequent mutations (e.g., Mediterranean B−) 
cannot be ruled out.
These findings are consistent with a recent review of 
the literature from Latin America and the Caribbean, 
Table 5 Number of  G6PD alleles among  malaria-infected 
individuals according to sex
n (%) Genotype
G6PDA− G6PDA+ G6PD B (wildtype)
Male 184 (46.23) 16 (4.02) 4 (1.01) 164 (41.21)
Female 214 (53.77) 31 (7.79) 13 (3.27) 170 (42.71)
Total 398 (100) 47 (11.81) 17 (4.27) 334 (83.92)
Fig. 2 Distribution of G6PD variants from malaria‑infected individuals.
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which concluded that the predominant genetic vari-
ant was A− (81.1% of the surveyed population) [25]; the 
same variant described in this study with 47 out of 66 
samples showing a mutation (71.21%). According to this 
review, five countries have documented low prevalence 
rates of G6PDd (Argentina, Bolivia, Mexico, Peru, and 
Uruguay) whereas a prevalence >10% has been reported 
in four Caribbean islands, and some areas of Brazil, 
Colombia, and Cuba [25].
In the present study, the overall frequency of the 
deficient “African” genotype A− is greater than previ-
ous reports from highly prevalent areas in the Latin 
American subcontinent. These findings suggests that, 
as observed in other tropical regions of Latin America, 
G6PD deficiency is a common condition in Honduras, 
especially in areas that are inhabited by peoples of Afri-
can descent.
In terms of the distribution of G6DPd by sex, the find-
ings of the present study are in agreement with current 
global estimates. Recently, Howes et  al. [7], applied a 
Bayesian geostatistical model to predict the allelic fre-
quency in malaria endemic countries of class II and III 
G6PDd in both hemizygous men and homozygous or 
heterozygous women. They estimated that the frequency 
in hemizygous male population of Honduras could range 
from 100,000 to 500,000 (1.2–6% of the population). This 
projection holds true for the present study, as 4% of sam-
ples from male patients were hemizygous A−.
In terms of the proportion of hemizygous males com-
pared with deficient females (either homozygous or het-
erozygous), both Howes et al. [7] and Monteiro et al. [25] 
coincide in a global estimate of 1:1.7. This estimate is also 
in agreement with the findings of the present study in 
which a 1:1.8 male:female ratio was found for deficient 
individuals.
Unfortunately, the lack of published data from most 
Central American countries prevents us from establish-
ing sub-regional comparisons. A single publication from 
Panama reports the analysis of 75 children with G6PDd 
detected by neonatal screening. Eighty percent of these 
children had an A−202A/376G genotype, while the remain-
ing 20% had A−376 G/968C or Mediterranean B− geno-
types [26]. Another study from Costa Rica analyzed 289 
Afro descendants from Port Limon, of which 28 (9.69%) 
had the “African” genotype A−202A [29]. Altogether these 
results suggest that G6PD A− genotype might be the 
most common in Honduras, Panama and Costa Rica.
Table 6 G6PD variants by geographical origin
Department n G6PD genotype n (%) Heterozygous Homozygous Hemizygous
Atlántida 35 A− 1 (2.86) 0 0 1
A+ 3 (8.57) 1 0 2
B 31 (88.57)
Colón 45 A− 2 (4.44) 0 2 0
A+ 3 (6.67) 3 0 0
B 40 (88.89)
Gracias a Dios 133 A− 31 (23.3) 17 3 11
A+ 7 (5.3) 4 1 2
B 95 (71.4)
Islas de la Bahía 107 A− 10 (9.35) 6 1 3
A+ 3 (2.80) 3 0 0
B 94 (87.85)
Olancho 78 A− 3 (3.85) 2 0 1
A+ 1 (1.28) 1 0 0
B 74 (94.87)
Total 398 A− 47 (11.81) 25 6 16
A+ 17 (4.27) 12 1 4
B 334 (83.92)
Table 7 Comparison of  two molecular techniques for  the 
detection of G6PD variants
Measure of agreement Kappa = 0.923 with asymptotic Std. Error = 0.052 (not 
assuming the null hypothesis).
Solgent kit PCR–RFLP
G6PD A− G6PD A+ Total
G6PD A− 47 (72.3%) 1 (1.5%) 48 (73.8%)
G6PD A+ 0 16 (24.6%) 16 (24.6%)
G6PD Santamaria 0 1 (1.5%) 1 (1.5%)
Total 47 (72.3%) 18 (27.7%) 65 (100%)
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The distribution of G6PDd variants in malaria endemic 
areas of Honduras shows two departments with higher allele 
frequencies: Gracias a Dios (38/133, 28.6%) and Islas de la 
Bahía (13/107, 12.2%). In contrast with the rest of the coun-
try, where the population is predominantly Mestizo, Islas de 
la Bahía has a higher proportion of Afro descendant people 
(the English-speaking and Garifuna communities); whereas 
Gracias a Dios is largely inhabited by the Miskitos, an ethnic 
group with distant African Ancestry but nowadays consid-
ered Amerindian, an indigenous community [2, 40]. These 
data are consistent with the geostatistical model-based map 
proposed by Howes et  al. [7] for African countries. They 
estimated that up to 37.5% of the sub-Saharan African ter-
ritories would present an average prevalence of 10% while 
some countries would have a much higher prevalence, for 
instance Nigeria, where G6PDd prevalence could reach up 
to 31% [7]. In Honduras, it is believed that the ancestors of 
Afro descendant (Garifuna) populations originally came 
from Nigeria, which could explain the higher prevalence of 
G6PDd in some geographic areas of the country.
Without information on the ethnicity of the study sam-
ples, explaining the high proportion of the A− genotype 
found is difficult. However, based on current population 
demographics originating from colonization and post-
colonization periods, it could be expected that a country-
wide G6PDd survey would confirm higher prevalence of 
the “African” genotype in the same departments.
The high frequency of the G6PD A− variant among 
malaria patients in Honduras lends support to the well-
known hypothesis correlating their geographical distri-
bution [41–43]. Several studies suggest that the G6PDd 
provides protection against Plasmodium spp. infection 
in non-immune adults [42, 44, 45]. Further, population 
genetic analyses of the G6PD locus indicate that these 
mutations have arisen recently in certain geographical 
areas as a result of positive selection exerted by malaria 
[46–49]. Based on these observations, it could be pre-
dicted that the prevalence of G6PDd variants would be 
higher in the Atlantic coast of Honduras where the inci-
dence of malaria is higher relative to the rest of the coun-
try [50]. Naturally, additional research utilizing a more 
representative sample of the Honduran population is 
warranted to confirm our findings.
Future prevalence studies of the general popula-
tion should also endeavor to include samples from both 
malaria-negative individuals and individuals residing 
in non-endemic areas of the country. Lacking these ref-
erence groups is an important limitation of the present 
study. Notwithstanding, our results suggest that a signifi-
cant sector of the Honduran population might potentially 
be at risk of adverse effects due to PQ treatment.
The use of 8-aminoquinolines in individuals with 
G6PDd has the potential to trigger adverse clinical 
effects, and therefore it would not be reasonable nor 
responsible to give one of these drugs before analyzing 
the patient’s G6PD status [51]. However, the severity of 
side effects of 8-aminoquinolines varies considerably 
depending on the deficient G6PD phenotype [52] as well 
as the dose of the drug [53, 54].
Four percent of the individuals analysed here were 
G6PDd A− hemizygous males while 1% of them were 
homozygous females. These individuals could be poten-
tially harmed by the administration of PQ, the only drug 
available in Honduras to eliminate liver P. vivax hypno-
zoites (and thus prevent relapses). In terms of PQ, the 
Honduran national regulation for malaria control estab-
lishes that treatment should consist of 0.25  mg/kg/day 
for 14 days to patients with uncomplicated vivax malaria, 
and 0.75 mg/kg as single dose the first day of treatment 
for a P. falciparum infection [4]. This regulation follows 
international recommendations and is considered safe 
for individuals with G6PDd [55]. This treatment scheme 
seems to trigger fewer adverse effects than others of 
shorter duration but with higher PQ doses, as described 
in the National regulation of Honduras’s neighbouring 
countries.
Based on the importance that malaria elimination pro-
grams have acquired [56], Monteiro et  al. have recently 
published a systematic review concerning the clini-
cal complications of G6PDd in Latin America [54]. The 
review revealed that although the number of complica-
tions reported after PQ intake was low—probably due 
to misreporting or inappropriate diagnosis—haemolysis 
was the most common complication among PQ-treated 
G6PDd-individuals in Latin America.
While the number of complicated cases triggered by 
PQ could be low, the risk of haemolysis in individuals 
with a class II or III deficiency might override the ben-
efits of malaria treatment. In turn, failure to treat malaria 
may put the patient at risk of serious clinical disease [17]. 
Hence, prior determination of G6PD status is necessary 
before the prescription of 8-aminoquinoline drugs, such 
as PQ, or more recently tafenoquine (TQ), a drug in its 
final phase of development as a promising anti-malarial 
agent [57–59].
The diagnosis and management of G6PDd is cur-
rently limited by cost, infrastructure and logistics. Fast, 
low-cost, and easy techniques are urgently needed for 
malaria-endemic countries such as Honduras. This is par-
ticularly true for remote, high-transmission areas where 
disadvantaged populations of African descent reside, as 
they might be more at risk of developing PQ-triggered 
haemolytic events [60, 61]. National policies establishing 
malaria management with oxidizing drugs such as PQ or 
TQ ought to be informed by research evidence concern-
ing the frequency of local G6PDd variants.
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Conclusions
This study documented for the first time the frequencies 
of the G6PDd A+ and A− genotypes through two geno-
typic approaches among malaria-infected individuals in 
Honduras. These frequencies were higher than the aver-
age expected for Latin America. Although ethnic groups 
potentially carrying genetic mutations in the G6PDd 
gene might have been overrepresented in this study, 
these populations reside in areas where malaria transmis-
sion is the highest in the country. Therefore, this report 
highlights the need for immediate research to determine 
whether these populations are at risk of PQ-triggered 
haemolytic complications. Additionally, our findings con-
tribute to filling the knowledge gaps regarding the distri-
bution and diversity of G6PD variants in Latin America.
Abbreviations
G6PD: glucose‑6‑phosphate dehydrogenase; G6PDd: glucose‑6‑phosphate 
dehydrogenase deficiency/deficient; NADPH: nicotinamide adenine dinucleo‑
tide phosphate reduced; PQ: primaquine; TQ: tafenoquine; WHO: World Health 
Organization; UNAH: National Autonomous University of Honduras; PCR: 
polymerase chain reaction; 18S rRNA: 18S ribosomal RNA; RFLP: restriction 
fragment length polymorphism; OMIM: online Mendelian inheritance in man; 
SNP: single nucleotide polymorphism.
Authors’ contributions
GF and REM conceived the research idea. MZ, ALS, WSO and GF participated in 
the design of the study. REM supervised the field work. MZ and GF performed 
the laboratory work. MZ, ALS, WSO and GF analysed and interpreted the data. 
MZ, GF and ALS wrote manuscript. All authors read and approved the final 
manuscript.
Author details
1 Microbiology Research Institute, National Autonomous University of Hon‑
duras, UNAH, Boulevard Suyapa, J1 Building, 4th Fl. Tegucigalpa, Francisco 
Morazán, Honduras. 2 Pan American Health Organization, Tegucigalpa, Hondu‑
ras. 3 Department Health Sciences, Brock University, 500 Glenridge Avenue, St 
Catharines, Ontario, ON L2S 3A1, Canada. 
Acknowledgements
Funding for this study was provided by UNAH’s Scientific Research Directorate 
(DICYP‑UNAH), Honduras.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 14 April 2015   Accepted: 28 July 2015
References
 1. WHO (2014) World malaria report 2014. World Health Organization, 
Geneva
Additional files
Additional file 1: STROBE statement.
Additional file 2: Flowchart with overall study findings.
 2. Faúndez A, Ely Meléndez (2011) Pueblos afrodescendientes de Honduras. 
(Secretaría de Desarrollo de los Pueblos Indígenas y Afrohondureños 
CMdA ed. pp. 52). SEDINAFROH, La Ceiba, p 52
 3. Price RN, Douglas NM, Anstey NM, von Seidlein L (2011) Plasmo‑
dium vivax treatments: what are we looking for? Curr Opin Infect Dis 
24:578–585
 4. Honduras SdSd (2010) Norma de Malaria en Honduras. (Subsecretaría de 
Riesgos Poblacionales DGdPdlS, Programa Nacional de la Prevención y 
Control de la Malaria ed., 1st edition). Tegucigalpa, Honduras
 5. Alving AS, Carson PE, Flanagan CL, Ickes CE (1956) Enzymatic deficiency 
in primaquine‑sensitive erythrocytes. Science 124:484–485
 6. Clyde DF (1981) Clinical problems associated with the use of primaquine 
as a tissue schizontocidal and gametocytocidal drug. Bull World Health 
Organ 59:391–395
 7. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M et al (2012) 
G6PD deficiency prevalence and estimates of affected populations in 
malaria endemic countries: a geostatistical model‑based map. PLoS Med 
9:e1001339
 8. Manjurano A, Sepulveda N, Nadjm B, Mtove G, Wangai H, Maxwell C et al 
(2015) African glucose‑6‑phosphate dehydrogenase alleles associated 
with protection from severe malaria in heterozygous females in Tanzania. 
PLoS Genet 11:e1004960
 9. Luzzatto L, Notaro R (2001) Malaria. Protecting against bad air. Science 
293:442–443
 10. Cappellini MD, Fiorelli G (2008) Glucose‑6‑phosphate dehydrogenase 
deficiency. Lancet 371:64–74
 11. Kletzien RF, Harris PK, Foellmi LA (1994) Glucose‑6‑phosphate dehydro‑
genase: a “housekeeping” enzyme subject to tissue‑specific regulation by 
hormones, nutrients, and oxidant stress. FASEB J 8:174–181
 12. Mehta A, Mason PJ, Vulliamy TJ (2000) Glucose‑6‑phosphate dehydroge‑
nase deficiency. Baillieres Best Pract Res Clin Haematol 13:21–38
 13. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E 
(2012) Glucose‑6‑phosphate dehydrogenase (G6PD) mutations database: 
review of the “old” and update of the new mutations. Blood Cells Mol Dis 
48:154–165
 14. Beutler E, Vulliamy T, Luzzatto L (1996) Hematologically important muta‑
tions: glucose‑6‑phosphate dehydrogenase. Blood Cells Mol Dis 22:49–56
 15. Vulliamy TJ, D’Urso M, Battistuzzi G, Estrada M, Foulkes NS, Martini G et al 
(1988) Diverse point mutations in the human glucose‑6‑phosphate dehy‑
drogenase gene cause enzyme deficiency and mild or severe hemolytic 
anemia. Proc Natl Acad Sci USA 85:5171–5175
 16. WHO Working Group (1989) Glucose‑6‑phosphate dehydrogenase 
deficiency. Bull World Health Organ 67:601–611
 17. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI (2013) G6PD defi‑
ciency: global distribution, genetic variants and primaquine therapy. Adv 
Parasitol 81:133–201
 18. Luzzatto L (2009) Glucose‑6‑phosphate dehydrogenase deficiency. In: 
Orkin SH, Nathan DG, Ginsburg D (eds) Nathan and Oski’s hematology of 
infancy and childhood. Saunders, Philadelphia
 19. Yoshida A, Beutler E, Motulsky AG (1971) Human glucose‑6‑phosphate 
dehydrogenase variants. Bull World Health Organ 45:243–253
 20. Ruwende C, Hill A (1998) Glucose‑6‑phosphate dehydrogenase defi‑
ciency and malaria. J Mol Med (Berl) 76:581–588
 21. Beutler E, Kuhl W, Vives‑Corrons JL, Prchal JT (1989) Molecular heteroge‑
neity of glucose‑6‑phosphate dehydrogenase A. Blood 74:2550–2555
 22. Hirono A, Beutler E (1988) Molecular cloning and nucleotide sequence of 
cDNA for human glucose‑6‑phosphate dehydrogenase variant A(−). Proc 
Natl Acad Sci USA 85:3951–3954
 23. Johnson MK, Clark TD, Njama‑Meya D, Rosenthal PJ, Parikh S (2009) 
Impact of the method of G6PD deficiency assessment on genetic asso‑
ciation studies of malaria susceptibility. PLoS One 4:e7246
 24. Porter IH, Boyer SH, Watson‑Williams EJ, Adam A, Szeinberg A, Siniscalco 
M (1964) Variation of glucose‑6‑phosphate dehydrogenase in different 
populations. Lancet 1:895–899
 25. Monteiro WM, Val FF, Siqueira AM, Franca GP, Sampaio VS, Melo GC et al 
(2014) G6PD deficiency in Latin America: systematic review on preva‑
lence and variants. Mem Inst Oswaldo Cruz 109:553–568
 26. Cossio‑Gurrola G, Arambula‑Meraz E, Perea M, Garcia N, Correa AS, Rueda 
K et al (2010) Glucose‑6‑phosphate dehydrogenase (G6PD) molecular 
variant deficiency: identification in Panama pediatric population. Blood 
Cells Mol Dis 44:115–116
Page 10 of 10Zúñiga et al. Malar J  (2015) 14:308 
 27. Elizondo J, Saenz GF, Paez CA, Ramon M, Garcia M, Gutierrez A et al (1982) 
G6PD‑Puerto Limon: a new deficient variant of glucose‑6‑phosphate 
dehydrogenase associated with congenital nonspherocytic hemolytic 
anemia. Hum Genet 62:110–112
 28. Azofeifa J, Barrantes R (1991) Genetic variation in the Bribri and Cabecar 
Amerindians from Talamanca, Costa Rica. Rev Biol Trop 39:249–253
 29. Beutler E, Kuhl W, Saenz GF, Rodriguez W (1991) Mutation analysis of 
glucose‑6‑phosphate dehydrogenase (G6PD) variants in Costa Rica. Hum 
Genet 87:462–464
 30. Saenz GF, Chaves M, Berrantes A, Elizondo J, Montero AG, Yoshida A 
(1984) A glucose‑6‑phosphate dehydrogenase variant, Gd(−) Santamaria 
found in Costa Rica. Acta Haematol 72:37–40
 31. Larranaga N, Mejia RE, Hormaza JI, Montoya A, Soto A, Fontecha GA 
(2013) Genetic structure of Plasmodium falciparum populations across 
the Honduras‑Nicaragua border. Malar J 12:354
 32. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P (1992) A one‑
step microbial DNA extraction method using “Chelex 100” suitable for 
gene amplification. Res Microbiol 143:785–790
 33. Singh B, Bobogare A, Cox‑Singh J, Snounou G, Abdullah MS, Rahman HA 
(1999) A genus‑ and species‑specific nested polymerase chain reaction 
malaria detection assay for epidemiologic studies. Am J Trop Med Hyg 
60:687–692
 34. Settin A, Elsobky E, Hammad A, Al‑Erany A (2008) Rapid sex determina‑
tion using PCR technique compared to classic cytogenetics. Int J Health 
Sci (Qassim) 2:49–52
 35. Mombo LE, Ntoumi F, Bisseye C, Ossari S, Lu CY, Nagel RL et al (2003) 
Human genetic polymorphisms and asymptomatic Plasmodium falcipa-
rum malaria in Gabonese schoolchildren. Am J Trop Med Hyg 68:186–190
 36. Luzzatto L MA (1989) Human erythrocyte glucose‑6‑phosphate dehy‑
drogenase deficiency. In: Scriver CR, Baudet AL, Sly WS, Valle D (eds) The 
metabolic basis of inherited disease, 6th edn. McGraw‑Hill, New York
 37. Kearse M, Moir R, Wilson A, Stones‑Havas S, Cheung M, Sturrock S et al 
(2012) Geneious Basic: an integrated and extendable desktop software 
platform for the organization and analysis of sequence data. Bioinformat‑
ics 28:1647–1649
 38. Online Mendelian Inheritance in Man®. http://www.omim.org
 39. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke 
JP et al (2008) The Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) statement: guidelines for reporting observa‑
tional studies. Rev Esp Salud Publica 82:251–259
 40. Herrera‑Paz EF, Matamoros M, Carracedo A (2010) The Garifuna (Black 
Carib) people of the Atlantic coasts of Honduras: population dynamics, 
structure, and phylogenetic relations inferred from genetic data, migra‑
tion matrices, and isonymy. Am J Hum Biol 22:36–44
 41. Sirugo G (2013) Reassessing an old claim: natural selection of hemizy‑
gotes and heterozygotes for G6PD deficiency in Africa by resistance to 
severe malaria. Am J Hematol 88:436
 42. Greene LS, McMahon L, DiIorio J (1993) Co‑evolution of glucose‑6‑phos‑
phate dehydrogenase deficiency and quinine taste sensitivity. Ann Hum 
Biol 20:497–500
 43. Luzzatto L (2012) G6PD deficiency and malaria selection. Heredity (Edinb) 
108:456
 44. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA (2007) 
X‑linked G6PD deficiency protects hemizygous males but not heterozy‑
gous females against severe malaria. PLoS Med 4:e66
 45. Tishkoff SA, Varkonyi R, Cahinhinan N, Abbes S, Argyropoulos G, Destro‑
Bisol G et al (2001) Haplotype diversity and linkage disequilibrium at 
human G6PD: recent origin of alleles that confer malarial resistance. 
Science 293:455–462
 46. Sabeti PC, Reich DE, Higgins JM, Levine HZ, Richter DJ, Schaffner SF et al 
(2002) Detecting recent positive selection in the human genome from 
haplotype structure. Nature 419:832–837
 47. Kwiatkowski DP (2005) How malaria has affected the human genome 
and what human genetics can teach us about malaria. Am J Hum Genet 
77:171–192
 48. Saunders MA, Slatkin M, Garner C, Hammer MF, Nachman MW (2005) The 
extent of linkage disequilibrium caused by selection on G6PD in humans. 
Genetics 171:1219–1229
 49. Hedrick PW (2011) Population genetics of malaria resistance in humans. 
Heredity (Edinb) 107:283–304
 50. Mejia Torres RE, Franco Garcia DN, Fontecha Sandoval GA, Hernandez 
Santana A, Singh P, Mancero Bucheli ST et al (2014) Prevalence and 
intensity of soil‑transmitted helminthiasis, prevalence of malaria and 
nutritional status of school going children in honduras. PLoS Negl Trop 
Dis 8:e3248
 51. Luzzatto L, Seneca E (2014) G6PD deficiency: a classic example of 
pharmacogenetics with on‑going clinical implications. Br J Haematol 
164:469–480
 52. Luzzatto L (2006) Glucose 6‑phosphate dehydrogenase deficiency: from 
genotype to phenotype. Haematologica 91:1303–1306
 53. Beutler E (1959) The hemolytic effect of primaquine and related com‑
pounds: a review. Blood 14:103–139
 54. Monteiro WM, Franca GP, Melo GC, Queiroz AL, Brito M, Peixoto HM et al 
(2014) Clinical complications of G6PD deficiency in Latin American and 
Caribbean populations: systematic review and implications for malaria 
elimination programmes. Malar J 13:70
 55. Committee WHOMPA, Secretariat (2012) Malaria Policy Advisory Commit‑
tee to the WHO: conclusions and recommendations of September 2012 
meeting. Malar J 11:424
 56. Panamerican Health Organization/World Health Organization sDCrSotRC 
(2011) Strategy and plan of action for Malaria. Provisional Agenda Item 
4.8. pp. 24. Washington DC, USA, p 24
 57. Marcsisin SR, Sousa JC, Reichard GA, Caridha D, Zeng Q, Roncal N et al 
(2014) Tafenoquine and NPC‑1161B require CYP 2D metabolism for 
anti‑malarial activity: implications for the 8‑aminoquinoline class of anti‑
malarial compounds. Malar J 13:2
 58. Llanos‑Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, 
Kochar SK et al (2014) Tafenoquine plus chloroquine for the treatment 
and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multi‑
centre, double‑blind, randomised, phase 2b dose‑selection study. Lancet 
383:1049–1058
 59. Kitchener S, Nasveld P, Edstein MD (2007) Tafenoquine for the treatment 
of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg 76:494–496
 60. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J et al 
(2013) Review of key knowledge gaps in glucose‑6‑phosphate dehydro‑
genase deficiency detection with regard to the safe clinical deployment 
of 8‑aminoquinoline treatment regimens: a workshop report. Malar J 
12:112
 61. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S et al (2011) Perfor‑
mance of the CareStart G6PD deficiency screening test, a point‑of‑care 
diagnostic for primaquine therapy screening. PLoS One 6:e28357
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
